enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. SGLT2 inhibitor - Wikipedia

   en.wikipedia.org/wiki/SGLT2_inhibitor

   Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...

3. Sotagliflozin - Wikipedia

   en.wikipedia.org/wiki/Sotagliflozin

   Sotagliflozin, sold under the brand name Inpefa among others, is a medication used to reduce the risk of death due to heart failure. [1] It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. [1]

4. Empagliflozin - Wikipedia

   en.wikipedia.org/wiki/Empagliflozin

   Empagliflozin lowers risk of hospitalization and death in people with reduced heart function, when added to standard heart failure treatment with or without type 2 diabetes. [ 29 ] [ 30 ] [ 31 ] It is indicated in adults with type 2 diabetes and established cardiovascular disease to reduce the risk of cardiovascular death; and as an adjunct to ...

5. Pairing Drugs Like Ozempic with SGLT2 Meds May Help ... - AOL

   www.aol.com/pairing-drugs-ozempic-sglt2-meds...

   Combining GLP-1 drugs like Ozempic with SGLT2 diabetes medications may help reduce the risk of heart attacks, stroke, and kidney disease, new research suggests.

6. Top aging expert says these 4 FDA-approved drugs hold promise ...

   www.aol.com/finance/global-aging-doctor-says-4...

   The drugs, while used to treat diabetes, show promise in reducing the risk of age-related diseases and kidney disease, by reducing oxidative stress and inflammation, and improving heart health and ...

7. Sodium/glucose cotransporter 2 - Wikipedia

   en.wikipedia.org/wiki/Sodium/glucose_cotransporter_2

   SGLT2 is a member of the sodium glucose cotransporter family, which are sodium-dependent glucose transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney. [6] SGLT2 is located in the early proximal tubule, and is responsible for reabsorption of 80-90% of the glucose filtered by the kidney glomerulus. [7]